Company Description
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide.
The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products.
In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices.
Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
It sells its products through direct sales, service forces, independent distributors, and sales representatives.
The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| Founded | 1985 |
| IPO Date | Jun 21, 1990 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 6,990 |
| CEO | Stephen MacMillan |
Contact Details
Address: 250 Campus Drive Marlborough, Massachusetts 01752 United States | |
| Phone | 508 263 2900 |
| Website | hologic.com |
Stock Details
| Ticker Symbol | HOLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000859737 |
| CUSIP Number | 436440101 |
| ISIN Number | US4364401012 |
| Employer ID | 04-2902449 |
| SIC Code | 3844 |
Key Executives
| Name | Position |
|---|---|
| Stephen P. MacMillan | Chairman, Chief Executive Officer and President |
| Karleen M. Oberton CPA | Chief Financial Officer |
| Essex D. Mitchell | Chief Operating Officer |
| Jan Verstreken | Group President of International |
| Paul Malenchini | Chief Information Officer |
| Michael J. Watts | Corporate Vice President of Investor Relations |
| Anne Liddy | General Counsel |
| Diana De Walt SPHR | Senior Vice President of Global Human Resources |
| Monica Aguirre Berthelot | Vice President and Chief of Staff |
| Dr. Jennifer M. Schneiders Ph.D. | Division President of Diagnostic Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2025 | 8-K | Current Report |
| Jul 8, 2025 | SCHEDULE 13G/A | Filing |
| May 23, 2025 | SD | Form - SD |
| May 2, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |